Modulators of Endogenous Neuroprotection: Estrogen, Corticotropin-releasing Hormone and Endocannabinoids

  • Christian Behl
Conference paper
Part of the Research and Perspectives in Endocrine Interactions book series (RPEI)


Age-associated neurodegenerative disorders are among the most challenging problems of our aging society. Alzheimer’s disease is affecting people with increasing frequency, since there is a clear relationship between the incidence of this detrimental disorder and age. Other neurodegenerative disorders, including Parkinson’s disease, stroke and amyotrophic lateral sclerosis, are also frequently observed in our aging society. For most of these diseases, no causal therapy has yet been identified. Many of the treatments given to patients that are affected by these disorders have different side effects, and therefore the search is on to identify novel molecular approaches that may lead to a more effective therapy. In addition to treatment after the onset of these disorders, preventive strategies are of great importance. The brain itself may lead us to such novel preventive avenues, since large areas of the brain and the central nervous system in general resist detrimental processes and remain functional, even in late stages of the disorders mentioned. Such intrinsic neuroprotective and neuropreventive signals may indeed help to stabilize brain function and to make the central nervous system more resistant to the development of neurodegenerative disorders. Among these signals, we identified a potent neuroprotective role for the female sex hormone, estrogen, the corticotropin-releasing hormone (CRH) and endogenously produced and secreted cannabinoids (endocannabinoids). These hormones are powerful neuroprotective compounds when applied in paradigms of oxidative nerve cell death. Oxidative stress is a major hallmark of many neurodegenerative processes and of aging in general. The identification of common downstream pathways induced by these hormones may be the basis for the development of novel molecular strategies for neuroprevention.


Estrogen Receptor Amyotrophic Lateral Sclerosis cAMP Response Element Binding Estrogen Receptor Alpha Amyloid Beta Protein 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Bayatti N, Zschocke J, Behl C (2003) Brain region-specific neuroprotective action and signaling of corticotropin-releasing hormone in primary neurons. Endocrinoloy 144:4051–4060CrossRefGoogle Scholar
  2. Behan DP, Grigoriadis DE, Lovenberg T, Chalmers D, Heinrichs S, Liaw C, De Souza EB. (1996) Neurobiology of corticotropin releasing factor (CRF) receptors and CRF-binding protein: implications for the treatment of CNS disorders. Mol Psychiat 1:265–277Google Scholar
  3. Behl C (2002) Estrogen as a neuroprotective hormone. Nature Rev Neurosci, 3:433–442Google Scholar
  4. Behl C, Widmann M, Trapp T, Holsboer F (1995) 17-beta estradiol protects neurons from oxidative stress-induced cell death in vitro. Biochem Biophys Res Commun 216: 473–82CrossRefPubMedGoogle Scholar
  5. Behl C, Skutella T, Lezoualc’h F, Post A, Widmann M, Newton C, Holsboer F (1997) Neuroprotection against oxidative stress by estrogens: structure-activity relationship. Mol Pharmacol 51: 535–541PubMedGoogle Scholar
  6. Dawson TL, Dawson VL (2003) Molecular pathways of neurodegeneration in Parkinson’s disease. Science 302: 819–822PubMedGoogle Scholar
  7. Holsboer F (2003) The role of peptides in treatment of psychiatric disorders. J Neural Transm Suppl. 64: 17–34PubMedGoogle Scholar
  8. Lezoualc’h F, Engert S, Berning B, Behl C (2000) Corticotropin-releasing hormone-mediated neuroprotection against oxidative stress is associated with the increased release of non-amyloidogenic amyloid beta precursor protein and with the suppression of nuclear factor-kappaB. Mol Endocrinol 14: 147–159CrossRefPubMedGoogle Scholar
  9. Lutz B (2002) Molecular biology of cannabinoid receptors. Prostaglandins Leukot Essent Fatty Acids 66 123–142CrossRefPubMedGoogle Scholar
  10. Marsicano G, Goodenough S, Monory K, Hermann H, Eder M, Cannich A, Azad SC, Cascio MG, Gutierrez SO, van der Stelt M, López-Rodriguez ML, Casanova E, Schütz G, Zieglgänsberger W, Di Marzo V, Behl C, Lutz B (2003) CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 302: 84–88CrossRefPubMedGoogle Scholar
  11. McEwen BS (2001) Estrogen’s effects on the brain: multiple sites and molecular mechanisms. J Appl Physiol. 91: 2785–2801PubMedGoogle Scholar
  12. Moosmann B, Behl C (2002) Antioxidants as treatment for neurodegenerative disorders. Expert Opin Invest Drugs 11: 1407–1435CrossRefGoogle Scholar
  13. Prokai L, Prokai-Tatrai K, Perjesi P, Zharikova AD, Perez EJ, Liu R, Simpkins JW (2003) Quinol-based cyclic antioxidant mechanism in estrogen neuroprotection. Proc Natl Acad Sci USA 100:11741–11746CrossRefPubMedGoogle Scholar
  14. Sano M (2003) Noncholinergic treatment options for Alzheimer’s disease. J Clin Psychiat 64Suppl 9:23–28Google Scholar
  15. Vale W, Spiess J, Rivier C, Rivier J (1981) Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science 213:1394–1397PubMedGoogle Scholar
  16. Zschocke J, Manthey D, Bayatti N, van der Burg B, Goodenough S, Behl C (2002) Estrogen receptor alpha-mediated silencing of caveolin gene expression in neuronal cells. J Biol Chem 277: 38772–38780CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2005

Authors and Affiliations

  • Christian Behl
    • 1
  1. 1.Institute for Physiological Chemistry and PathobiochemistryJohannes Gutenberg University, Medical SchoolMainzGermany

Personalised recommendations